Sanofi has announced that it will be broadening its immunology pipeline by acquiring Dren Bio’s phase 1 CD20-directed ...

AstraZeneca (AZ) has announced that its immunotherapy Imfinzi (durvalumab) has been approved by the European Commission (EC) ...

Novartis also shared results from the open-label phase 3b STRENGTH study of OAV101 IT in SMA patients aged two to less than 18 years who had discontinued treatment with nusinersen or risdiplam, which ...

For example, developing a drug nowadays takes eight to ten years and costs over $2bn, yet less than 10% of clinical ...

The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...

AbbVie’s Elahere (mirvetuximab soravtansine-gynx) has demonstrated consistent survival benefits in a subset of ovarian cancer ...

The phase 3 REDEFINE 2 trial has been evaluating once-weekly subcutaneous CagriSema, a fixed dose combination of cagrilintide ...

Not many people would pay for a ticket to a concert where their seat was positioned behind a pillar and directly below the ...

PMLiVE’s Top Pharma List is live!; Omnichannel – breaking down the barriers; Rare diseases – improving patient access ...

AstraZeneca (AZ) has announced that it will be expanding its cell therapy capabilities by acquiring EsoBiotec for up to $1bn. The deal will give AZ access to EsoBiotec’s Engineered NanoBody Lentiviral ...

The National Institute for Health and Care Excellence (NICE) has recommended Pharming’s Joenja (leniolisib) to treat patients with the ultra-rare immune disease, activated phosphoinositide 3-kinase ...

Boehringer Ingelheim (BI) and Salipro Biotech have entered into a partnership aimed at accelerating the development of ...